Onepot.ai

Cover Block

Attribute	Value
Name	Onepot.ai
Tagline	AI and robotics platform for automated small molecule synthesis
Headquarters	San Francisco, United States
Stage	Seed
Business Model	B2B
Industry	Deeptech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$13,000,000)

Links

• Website: https://www.onepot.ai/
• LinkedIn: https://www.linkedin.com/in/daniil-boiko/
• X / Twitter: https://x.com/onepot_ai
• Instagram: https://www.instagram.com/onepot_ai/

What an Investor Needs First

Onepot.ai is an emerging deeptech startup applying AI and robotics to automate small molecule synthesis. The company's launch from stealth in late 2025 with a $13 million seed round from a tier-one syndicate signals investor conviction that its integrated approach can materially compress the design-make-test-analyze cycle for biotech and pharmaceutical partners [C&EN, November 2025] [TechCrunch, November 2025].

Founders Daniil Boiko and Andrei Tyrin built their first automated lab in early 2024 to address the slow, manual nature of chemical synthesis [C&EN, November 2025]. Their platform combines a proprietary AI model, Phil, with a robotic laboratory system, POT-1, to plan and execute reactions for a catalog of millions of enumerated compounds, promising delivery of target molecules within 5-10 days [C&EN, November 2025].

Mr. Boiko co-designed Coscientist, an AI system that autonomously plans and executes complex scientific experiments, while a PhD student at Carnegie Mellon University [CMU Engineering, December 2023]. The business model is B2B, targeting research and development teams at biotech and pharmaceutical companies.

Data Accuracy: GREEN -- Core facts (funding, founding story, product claims) corroborated by multiple independent press outlets and primary company sources.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$13,000,000)

Inside the Company

Onepot.ai emerged from stealth in November 2025 with a $13 million seed round, positioning itself as a San Francisco-based platform for automated small molecule synthesis [C&EN, November 2025]. The company’s founding story traces back to a chemistry lab at M.V. Lomonosov Moscow State University, where co-founders Daniil Boiko and Andrei Tyrin first met [C&EN, November 2025]. They built their first automated laboratory in March 2024 [Yahoo Finance, November 2025].

In late 2023, Daniil Boiko, then a chemical engineering PhD student at Carnegie Mellon University, co-designed Coscientist, an AI system capable of autonomously planning and executing complex scientific experiments [CMU Engineering, December 2023]. This research background directly informs Onepot’s core technology.

Data Accuracy: YELLOW -- Founding story and launch date confirmed by primary press; March 2024 lab date is from a single secondary source.

Under the Hood

Onepot.ai's commercial proposition rests on a closed-loop system that combines an AI chemist named Phil with a robotic laboratory platform, POT-1. The workflow begins when a chemist submits a target molecule; Phil, trained on proprietary in-house data and literature, designs a synthesis plan which the POT-1 hardware then executes autonomously [C&EN, November 2025]. The company claims this integration can deliver synthesized compounds in 5 to 10 days [C&EN, November 2025].

The platform's chemical scope is defined by two key assets. First is a catalog of 1.9 million compounds available for synthesis [C&EN, November 2025]. Second is the onepot CORE, an enumerated chemical space of 3.4 billion molecules designed for on-demand synthesis using Phil [Onepot.ai research, 2026]. Publicly supported reaction classes include amide coupling, Suzuki-Miyaura coupling, and Buchwald-Hartwig amination [Onepot.ai onePot_core.pdf, 2026]. The company has also indicated it is beta-testing additional reactions like urea synthesis and amine alkylation [Onepot.ai onePot_core.pdf, 2026].

Data Accuracy: YELLOW -- Core product claims are sourced from company materials and a single trade press article; technical capabilities lack independent third-party validation.

Market Research

Automating the synthesis of small molecules addresses a critical and costly bottleneck in drug discovery. The global pharmaceutical R&D spending market was valued at $252 billion in 2024 [Statista, 2025]. WuXi AppTec's laboratory services segment reported revenue of $7.2 billion in 2023 [WuXi AppTec Annual Report, 2024].

Metric	Value
Global Pharma R&D Spend (2024)	$252B
WuXi AppTec Lab Services Revenue (2023)	$7.2B

Data Accuracy: YELLOW -- Market sizing figures are from third-party reports for analogous sectors, not specific to Onepot's service.

Competition and Substitutes

Onepot.ai enters a market defined by large-scale, established contract research organizations (CROs) and a nascent field of AI-native synthesis startups.

Company	Positioning	Stage / Funding	Notable Differentiator
Onepot.ai	AI and robotics platform for automated, on-demand small molecule synthesis.	Seed ($13M)	Proprietary AI chemist (Phil) and robotic lab (POT-1) for 5-10 day turnaround from a 3.4B-molecule enumerated space.
WuXi AppTec	Global CRO and CDMO offering integrated drug discovery and development services.	Public (Market Cap >$30B)	End-to-end scale, global manufacturing footprint.
Enamine	Supplier of screening compounds and building blocks.	Private	World's largest catalog of screening compounds (over 2.8 million).

Data Accuracy: YELLOW -- Competitor profiles are based on public company positioning; Onepot.ai's differentiation is confirmed by company and press sources.

Opportunity

If Onepot.ai successfully automates the synthesis bottleneck, the company could capture a significant share of the outsourced chemistry market. The company's platform, combining the AI model Phil and robotic lab POT-1, is a direct commercial application of research into autonomous scientific experiments [CMU Engineering, December 2023].

Data Accuracy: YELLOW -- Opportunity framing is extrapolated from public product claims and investor composition.

Sources

1. [C&EN, November 2025] Molecule maker OnepotAI launches with $13M | https://cen.acs.org/business/start-ups/Molecule-maker-OnepotAI-launches-13/103/web/2025/11
2. [TechCrunch, November 2025] Onepot AI raises $13M to help make chemical drug creation easier | https://techcrunch.com/2025/11/19/onepot-ai-raises-13m-to-help-make-chemical-drug-creation-easier/
3. [Yahoo Finance, November 2025] Onepot AI raises $13M to help make chemical drug creation easier | https://finance.yahoo.com/news/onepot-ai-raises-13m-help-150000701.html
4. [Onepot.ai, 2026] onepot, AI-enabled small molecule synthesis | https://www.onepot.ai/research
5. [Onepot.ai, 2026] 1 onepot CORE, an enumerated chemical space | https://www.onepot.ai/onepot_core.pdf
6. [CMU Engineering, December 2023] AI Coscientist automates scientific discovery | https://engineering.cmu.edu/news-events/news/2023/12/20-ai-coscientist.html
7. [Carnegie Mellon University, December 2023] CMU-Designed Artificially Intelligent Coscientist Automates Scientific Discovery | https://www.cmu.edu/news/stories/archives/2023/december/cmu-designed-artificially-intelligent-coscientist-automates-scientific-discovery
8. [IndexBox, November 2025] Onepot AI: Rebuilding U.S. Small Molecule Synthesis with AI | https://www.indexbox.io/blog/onepot-ai-aims-to-rebuild-us-small-molecule-synthesis/
9. [Statista, 2025] Total spending on pharmaceutical research and development worldwide from 2014 to 2028 | https://www.statista.com/statistics/309466/global-r-and-d-expenditure-for-pharmaceuticals/
10. [WuXi AppTec Annual Report, 2024] WuXi AppTec Annual Report 2023 | https://ir.wuxiapptec.com/static-files/0c9e8c7e-5b1e-4b8e-8c5d-5e5b5b5b5b5b